The present invention relates to the adoptive therapy using notably CAR-T cells. Herethe inventors used a lentiviral vector approach to silence RINF […]

The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of […]

Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in […]

Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). To address this issue, the inventors generated a syngeneic […]

Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy […]

CAR macrophages (CAR-M) can phagocyte tumor cells expressing a target antigen. It is herein shown that the proprotein convertase furin is […]

Inventors have shown that targeting DDR1 and DDR2 collagen receptors by Imatinib resensitizes melanoma tumors to BRAFV600E to targeted therapy and […]

Cholesterol efflux pathways have anti-inflammatory and anti-proliferative properties that could be exploited in tumor biology to unravel cancer […]

Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell lymphomaaffects lymph nodes and extra-nodal sites with characteristic […]

Metastatic uveal melanomas are highly resistant to all existing treatments. Here, a kinome-wide CRISPR-Cas9 knockout screen, revealed that the […]